Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities around protein engineering and our solid intellectual property, which serve as the engine behind our XmAb® drug development programs. We engineer monoclonal antibodies and develop them in clinical studies for the potential treatment of patients with cancer and other serious diseases. Our XmAb technologies, consisting of small changes to the structure of monoclonal antibodies, enable new mechanisms of therapeutic action.

We have built a clinical pipeline of novel bispecific antibodies using our XmAb® bispecific Fc domain, including several bispecific T-cell engagers. These molecules bind to a tumor-associated antigen on cancer cells and to cytotoxic T cells, leading to the targeted killing of tumor cells by the immune system.

The plug-and-play nature of XmAb® Fc domains enables us to selectively provide access and license one or more XmAb technologies for our collaborators’ use in developing their own proprietary antibodies with improved properties. Over 20 drug candidates engineered with our XmAb technologies are in clinical development internally and with partners, which include Amgen, Genentech, and J&J Innovative Medicine, among others. Three marketed XmAb medicines have been developed with our protein engineering technologies.